Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
119 hedge funds and large institutions have $229M invested in Sucampo Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 29 closing their positions.
48% more call options, than puts
Call options by funds: $615K | Put options by funds: $416K
24% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 37
12% more capital invested
Capital invested by funds: $205M → $229M (+$24.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 136 → 119 (-17)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$14.7M |
| 2 |
Renaissance Technologies
New York
|
+$2.89M |
| 3 |
Millennium Management
New York
|
+$2.72M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$2.36M |
| 5 |
RA
Royce & Associates
New York
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$9.2M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$3.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.35M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.35M |
| 5 |
Morgan Stanley
New York
|
-$2.34M |
SCMP Hedge Fund Activity: Q3 2016 in Review
119 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q3 2016, worth a combined $229M — up 12% from $205M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SCMP and 13 opened new positions — a net loss of 16 holders — while 37 trimmed existing stakes and 46 added.
The largest buyer was LSV Asset Management, adding an estimated $14.7M. The largest seller was Acadian Asset Management, cutting an estimated $9.2M.
- 119 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q3 2016, down from 136 in Q2 2016.
- Funds reported $229M of Sucampo Pharmaceuticals, Inc. stock for Q3 2016, up 12% quarter-over-quarter.
- 13 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q3 2016 and 29 closed out, a net change of -16 holders.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q3 2016 was LSV Asset Management, an estimated $14.7M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q3 2016 was Acadian Asset Management, an estimated $9.2M sold.
Based on aggregated 13F filings for Q3 2016.